JPWO2020156437A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020156437A5 JPWO2020156437A5 JP2021543533A JP2021543533A JPWO2020156437A5 JP WO2020156437 A5 JPWO2020156437 A5 JP WO2020156437A5 JP 2021543533 A JP2021543533 A JP 2021543533A JP 2021543533 A JP2021543533 A JP 2021543533A JP WO2020156437 A5 JPWO2020156437 A5 JP WO2020156437A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- alkyl
- acceptable salt
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 229910052740 iodine Inorganic materials 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024161770A JP2024175091A (ja) | 2019-01-29 | 2024-09-19 | Ａｋｔ阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910084801.3 | 2019-01-29 | ||
| CN201910084801 | 2019-01-29 | ||
| PCT/CN2020/073798 WO2020156437A1 (zh) | 2019-01-29 | 2020-01-22 | Akt抑制剂 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024161770A Division JP2024175091A (ja) | 2019-01-29 | 2024-09-19 | Ａｋｔ阻害剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022517866A JP2022517866A (ja) | 2022-03-10 |
| JPWO2020156437A5 true JPWO2020156437A5 (https=) | 2023-02-01 |
| JP2022517866A5 JP2022517866A5 (https=) | 2023-02-01 |
| JP7617005B2 JP7617005B2 (ja) | 2025-01-17 |
Family
ID=71841634
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543533A Active JP7617005B2 (ja) | 2019-01-29 | 2020-01-22 | Ａｋｔ阻害剤 |
| JP2024161770A Withdrawn JP2024175091A (ja) | 2019-01-29 | 2024-09-19 | Ａｋｔ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024161770A Withdrawn JP2024175091A (ja) | 2019-01-29 | 2024-09-19 | Ａｋｔ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220144821A1 (https=) |
| EP (1) | EP3919491B1 (https=) |
| JP (2) | JP7617005B2 (https=) |
| KR (1) | KR102892239B1 (https=) |
| CN (2) | CN117964620A (https=) |
| AU (1) | AU2020214258B2 (https=) |
| CA (1) | CA3127884A1 (https=) |
| ES (1) | ES3037595T3 (https=) |
| PL (1) | PL3919491T3 (https=) |
| WO (1) | WO2020156437A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI908780B (zh) * | 2020-03-17 | 2025-12-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合二環類衍生物、其製備方法及其在醫藥上的應用 |
| CN115485276B (zh) * | 2020-05-15 | 2024-05-31 | 南京正大天晴制药有限公司 | 氘代akt激酶抑制剂 |
| CN119302960A (zh) * | 2020-07-22 | 2025-01-14 | 南京正大天晴制药有限公司 | Akt抑制剂的单位剂量组合物 |
| WO2022017448A1 (zh) * | 2020-07-22 | 2022-01-27 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型 |
| CN115836069B (zh) * | 2020-07-22 | 2024-02-06 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途 |
| CN116478156A (zh) * | 2022-01-17 | 2023-07-25 | 南京正大天晴制药有限公司 | 一种akt抑制剂化合物的富马酸盐晶型及其制备方法 |
| WO2024146599A1 (zh) * | 2023-01-06 | 2024-07-11 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途 |
| CN121586576A (zh) | 2023-06-14 | 2026-02-27 | 南京正大天晴制药有限公司 | Akt抑制剂在制备预防或治疗乳腺癌药物中的用途 |
| CN120157686A (zh) * | 2023-12-14 | 2025-06-17 | 南京正大天晴制药有限公司 | 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用 |
| CN121177294B (zh) * | 2025-11-27 | 2026-02-27 | 四川省医学科学院·四川省人民医院 | Akt抑制剂在制备诱导胰岛移植免疫耐受药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2546754A1 (en) * | 2003-11-21 | 2005-06-09 | Array Biopharma Inc. | Akt protein kinase inhibitors |
| US20130065908A1 (en) * | 2009-12-07 | 2013-03-14 | Array Biopharma Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
| UA95641C2 (xx) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
| EP2049500B1 (en) | 2006-07-06 | 2011-09-07 | Array Biopharma, Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| CA2711782C (en) | 2008-01-09 | 2017-01-03 | Array Biopharma Inc. | 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| MX2012004780A (es) * | 2009-10-23 | 2012-08-23 | Lilly Co Eli | Inhibidores de akt. |
| CA2890288A1 (en) * | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | Novel heterocyclic derivatives as modulators of kinase activity |
| AR093511A1 (es) * | 2012-11-16 | 2015-06-10 | Merck Patent Gmbh | Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas |
| EP3189036B1 (en) * | 2014-09-05 | 2023-07-19 | ArQule, Inc. | Compositions and methods for treating proliferation disorders |
| CN109020957B (zh) * | 2017-06-12 | 2023-01-13 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
| CN108503645A (zh) * | 2018-03-01 | 2018-09-07 | 山东大学 | 含氨甲基的哌嗪酮类化合物及其制备方法和应用 |
| ES2969982T3 (es) * | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
-
2020
- 2020-01-22 PL PL20748221.7T patent/PL3919491T3/pl unknown
- 2020-01-22 EP EP20748221.7A patent/EP3919491B1/en active Active
- 2020-01-22 CN CN202410142331.2A patent/CN117964620A/zh active Pending
- 2020-01-22 US US17/426,047 patent/US20220144821A1/en active Pending
- 2020-01-22 JP JP2021543533A patent/JP7617005B2/ja active Active
- 2020-01-22 CA CA3127884A patent/CA3127884A1/en active Pending
- 2020-01-22 WO PCT/CN2020/073798 patent/WO2020156437A1/zh not_active Ceased
- 2020-01-22 KR KR1020217027161A patent/KR102892239B1/ko active Active
- 2020-01-22 AU AU2020214258A patent/AU2020214258B2/en active Active
- 2020-01-22 CN CN202080005749.9A patent/CN113272304B/zh active Active
- 2020-01-22 ES ES20748221T patent/ES3037595T3/es active Active
-
2024
- 2024-09-19 JP JP2024161770A patent/JP2024175091A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2639064T3 (es) | Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa | |
| JP6432624B2 (ja) | ３環性ヘテロ環化合物及びｊａｋ阻害剤 | |
| JP2022527796A5 (https=) | ||
| ES2586588T3 (es) | Derivados tricíclicos, procedimiento para su preparación y su uso como inhibidores de quinasa | |
| JP2013523884A5 (https=) | ||
| TW202423440A (zh) | Ｋｒａｓ ｇ１２ｃ突變蛋白的系鏈之雜環抑制劑及其用途 | |
| WO2019165073A1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| JP2019534261A5 (https=) | ||
| IL292229A (en) | Pharmacological combination of prmt5 inhibitors | |
| JP2018522869A5 (https=) | ||
| JP2017503867A5 (https=) | ||
| JP2012532131A5 (https=) | ||
| EP3004109A1 (en) | Imidazopyrrolidinone derivatives and their use in the treatment of disease | |
| EA019869B1 (ru) | Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения | |
| JPWO2021107160A5 (https=) | ||
| JPWO2007126128A1 (ja) | ジヒドロピラゾロピリミジノン誘導体 | |
| JP2016520118A5 (https=) | ||
| CA2946833C (en) | Pyrrolopyrimidine compounds for prevention of tumors based on nae inhibitory effect | |
| JPWO2020156437A5 (https=) | ||
| JP2020526549A5 (https=) | ||
| CZ20032474A3 (cs) | Substituované pyrazolopyrimidiny a thiazolopyrimidiny, způsob jejich výroby, farmaceutické přípravky tyto látky obsahující a jejich použití | |
| CN107667092A (zh) | 作为fgfr4抑制剂的甲酰化n‑杂环衍生物 | |
| JP6284545B2 (ja) | Ｃｆｔｒ阻害としての三環式化合物 | |
| CN109843883A (zh) | 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途 | |
| JP2020536915A5 (https=) |